Essa Pharma Stock Analysis

EPIX Stock  USD 5.97  0.78  11.56%   
ESSA Pharma is undervalued with Real Value of 9.25 and Target Price of 19.4. The main objective of ESSA Pharma stock analysis is to determine its intrinsic value, which is an estimate of what ESSA Pharma is worth, separate from its market price. There are two main types of ESSA Pharma's stock analysis: fundamental analysis and technical analysis.
The ESSA Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ESSA Pharma is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. ESSA Stock trading window is adjusted to America/New York timezone.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

ESSA Stock Analysis Notes

About 79.0% of the company shares are held by institutions such as insurance companies. The book value of ESSA Pharma was currently reported as 3.01. The company recorded a loss per share of 0.62. ESSA Pharma last dividend was issued on the 25th of April 2018. The entity had 1:20 split on the 25th of April 2018. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States. To learn more about ESSA Pharma call David MD at 778 331 0962 or check out https://www.essapharma.com.

ESSA Pharma Investment Alerts

ESSA Pharma generated a negative expected return over the last 90 days
ESSA Pharma has high historical volatility and very poor performance
Net Loss for the year was (26.58 M) with profit before overhead, payroll, taxes, and interest of 0.
ESSA Pharma currently holds about 174.6 M in cash with (19.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96.
ESSA Pharma has a very weak financial position based on the latest SEC disclosures
Over 79.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: ESSA Pharma to Present at the Jefferies Global Healthcare Conference

ESSA Pharma Upcoming and Recent Events

Earnings reports are used by ESSA Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ESSA Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
10th of December 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

ESSA Largest EPS Surprises

Earnings surprises can significantly impact ESSA Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-08
2023-06-30-0.19-0.170.0210 
2016-02-12
2015-12-31-0.17-0.19-0.0211 
2024-02-13
2023-12-31-0.17-0.140.0317 
View All Earnings Estimates

ESSA Pharma Environmental, Social, and Governance (ESG) Scores

ESSA Pharma's ESG score is a quantitative measure that evaluates ESSA Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of ESSA Pharma's operations that may have significant financial implications and affect ESSA Pharma's stock price as well as guide investors towards more socially responsible investments.

ESSA Stock Institutional Investors

Shares
Parkman Healthcare Partners Llc2024-03-31
251.7 K
Cibc World Markets Inc.2024-03-31
80.9 K
D. E. Shaw & Co Lp2024-03-31
65.1 K
Bnp Paribas Arbitrage, Sa2023-12-31
57.5 K
American Century Companies Inc2024-03-31
46.2 K
Royal Bank Of Canada2024-03-31
30.8 K
Geode Capital Management, Llc2024-03-31
26.9 K
Renaissance Technologies Corp2023-12-31
24.2 K
Privium Fund Management (uk) Ltd2023-12-31
20 K
Bvf Inc2024-03-31
8.7 M
Bellevue Group Ag2024-03-31
7.9 M
Note, although ESSA Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ESSA Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 300 M.

ESSA Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.16)(0.17)
Return On Capital Employed(0.16)(0.17)
Return On Assets(0.16)(0.17)
Return On Equity(0.21)(0.20)

Management Efficiency

ESSA Pharma has return on total asset (ROA) of (0.144) % which means that it has lost $0.144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1914) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 201.8 M in 2024, whereas Other Current Assets are likely to drop slightly above 639.6 K in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 2.97  2.20 
Net Current Asset Value3.6 M3.2 M
Tangible Asset Value3.7 M3.3 M
Tangible Book Value Per Share 2.97  2.10 
Enterprise Value Over EBITDA(3.49)(3.66)
Price Book Value Ratio 0.84  0.88 
Enterprise Value Multiple(3.49)(3.66)
Price Fair Value 0.84  0.88 
Enterprise Value92.4 M97 M
The analysis of ESSA Pharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze ESSA Pharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of ESSA Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.759

Technical Drivers

As of the 3rd of June, ESSA Pharma shows the Mean Deviation of 2.64, market risk adjusted performance of (5.95), and Standard Deviation of 3.59. ESSA Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for thirteen technical drivers for ESSA Pharma, which can be compared to its peers. Please confirm ESSA Pharma market risk adjusted performance and treynor ratio to decide if ESSA Pharma is priced fairly, providing market reflects its regular price of 5.97 per share. Given that ESSA Pharma has information ratio of (0.19), we urge you to verify ESSA Pharma's prevailing market performance to make sure the company can sustain itself at some point in the future.

ESSA Pharma Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ESSA Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ESSA Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

ESSA Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ESSA Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ESSA Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ESSA Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ESSA Pharma Predictive Daily Indicators

ESSA Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ESSA Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

ESSA Pharma Corporate Filings

10Q
14th of May 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
F4
6th of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
25th of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
5th of April 2024
Other Reports
ViewVerify
F4
28th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
7th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
5th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of February 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify

ESSA Pharma Forecast Models

ESSA Pharma's time-series forecasting models are one of many ESSA Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ESSA Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About ESSA Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how ESSA Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ESSA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ESSA Pharma. By using and applying ESSA Stock analysis, traders can create a robust methodology for identifying ESSA entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin-53.9 K-56.6 K
Operating Profit Margin-81.5 K-85.5 K
Net Loss-54.5 K-57.2 K
Gross Profit Margin 0.00  0.00 

Current ESSA Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ESSA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ESSA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
19.4Strong Buy5Odds
ESSA Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most ESSA analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ESSA stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ESSA Pharma, talking to its executives and customers, or listening to ESSA conference calls.
ESSA Analyst Advice Details

ESSA Stock Analysis Indicators

ESSA Pharma stock analysis indicators help investors evaluate how ESSA Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ESSA Pharma shares will generate the highest return on investment. By understating and applying ESSA Pharma stock analysis, traders can identify ESSA Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow57.1 M
Common Stock Shares Outstanding44.1 M
Total Stockholder Equity145.6 M
Tax Provision1600.00
Property Plant And Equipment Net68 K
Cash And Short Term Investments148.1 M
Cash33.7 M
Accounts PayableM
Net Debt-33.6 M
50 Day M A7.0764
Total Current Liabilities3.5 M
Other Operating Expenses32.1 M
Non Current Assets Total325.3 K
Non Currrent Assets Other257.2 K
Stock Based CompensationM

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.